Abcellera Biologics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Abcellera Biologics Inc 公司

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Abcellera Biologics Inc簡介



公司代碼ABCL

公司名稱Abcellera Biologics Inc

上市日期Dec 11, 2020

CEOHansen (Carl L.G)

員工數量596

證券類型Ordinary Share

年結日Dec 11

公司地址150 W 4Th Avenue

城市VANCOUVER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Canada

郵編V5Y 1G6

電話16045599005

網址https://www.abcellera.com/

公司代碼ABCL

上市日期Dec 11, 2020

CEOHansen (Carl L.G)

Abcellera Biologics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Veronique Lecault, Ph.D.

Co-Founder, Chief Operating Officer, Director

9.61M

--

Mr. Andrew Booth

Chief Financial Officer

283.96K

--

Dr. Carl L.G. Hansen, Ph.D.

Chairman of the Board, President, Chief Executive Officer, Co-Founder

--

Mr. Tryn T. Stimart, J.D.

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer

--

Dr. Michael R. Hayden

Lead Independent Director

--

Mr. John S. Montalbano

Independent Director

--

Dr. Sarah B. Noonberg, M.D., Ph.D.

Chief Medical Officer

--

Mr. Stephen Quake

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Veronique Lecault, Ph.D.

Co-Founder, Chief Operating Officer, Director

9.61M

--

Mr. Andrew Booth

Chief Financial Officer

283.96K

--

Dr. Carl L.G. Hansen, Ph.D.

Chairman of the Board, President, Chief Executive Officer, Co-Founder

--

Mr. Tryn T. Stimart, J.D.

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer

--

Dr. Michael R. Hayden

Lead Independent Director

--

Mr. John S. Montalbano

Independent Director

--

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2024Q2

FY2023Q2

業務USD

名稱

營收

佔比

Research fees

8.82M

98.46%

Licensing revenue

138.00K

1.54%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Research fees

8.82M

98.46%

Licensing revenue

138.00K

1.54%

股東統計

更新時間: 1月25日週日

持股股東

股東類型

持股股東

佔比

Thermopylae Holdings Ltd

18.68%

Baker Bros. Advisors LP

9.20%

Capital World Investors

4.46%

Two Sigma Investments, LP

3.34%

Lecault (Veronique)

3.21%

其他

61.11%

持股股東

佔比

Thermopylae Holdings Ltd

18.68%

Baker Bros. Advisors LP

9.20%

Capital World Investors

4.46%

Two Sigma Investments, LP

3.34%

Lecault (Veronique)

3.21%

其他

61.11%

股東類型

持股股東

佔比

Corporation

18.68%

Hedge Fund

16.25%

Investment Advisor

9.46%

Individual Investor

4.29%

Investment Advisor/Hedge Fund

3.93%

Research Firm

2.06%

Bank and Trust

0.69%

Pension Fund

0.29%

Sovereign Wealth Fund

0.21%

其他

44.13%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

320

98.53M

32.92%

-53.59M

2025Q3

340

112.51M

51.75%

-3.28M

2025Q2

368

115.12M

53.94%

-18.45M

2025Q1

420

133.63M

52.62%

-23.37M

2024Q4

441

121.95M

50.14%

+4.83M

2024Q3

440

121.95M

51.59%

-4.54M

2024Q2

439

127.07M

51.27%

-6.55M

2024Q1

432

134.44M

53.43%

-22.43M

2023Q4

425

138.44M

60.93%

-1.40M

2023Q3

426

134.18M

60.12%

-4.59M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Thermopylae Holdings Ltd

55.92M

18.68%

-225.00K

-0.40%

Dec 18, 2025

Baker Bros. Advisors LP

27.53M

9.2%

--

Sep 30, 2025

Capital World Investors

13.36M

4.46%

--

Sep 30, 2025

Two Sigma Investments, LP

9.99M

3.34%

+1.81M

+22.09%

Sep 30, 2025

Lecault (Veronique)

9.61M

3.21%

--

Apr 01, 2025

ArrowMark Colorado Holdings, LLC

4.11M

1.37%

--

Sep 30, 2025

Renaissance Technologies LLC

3.36M

1.12%

+53.30K

+1.61%

Sep 30, 2025

Tang Capital Management, LLC

2.60M

0.87%

--

Sep 30, 2025

Morgan Stanley & Co. LLC

2.56M

0.85%

+1.79M

+234.13%

Sep 30, 2025

Millennium Management LLC

2.43M

0.81%

-967.85K

-28.49%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

2.64%

Virtus LifeSci Biotech Clinical Trials ETF

1.19%

ProShares Ultra Nasdaq Biotechnology

0.16%

Invesco Nasdaq Biotechnology ETF

0.16%

SPDR S&P International Small Cap ETF

0.12%

iShares Biotechnology ETF

0.11%

Invesco RAFI Developed Mkts ex-US SM ETF

0.05%

Avantis US Small Cap Equity ETF

0.01%

SPDR Portfolio Developed World ex-US ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0.01%

iShares Genomics Immunology and Healthcare ETF

佔比2.64%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.19%

ProShares Ultra Nasdaq Biotechnology

佔比0.16%

Invesco Nasdaq Biotechnology ETF

佔比0.16%

SPDR S&P International Small Cap ETF

佔比0.12%

iShares Biotechnology ETF

佔比0.11%

Invesco RAFI Developed Mkts ex-US SM ETF

佔比0.05%

Avantis US Small Cap Equity ETF

佔比0.01%

SPDR Portfolio Developed World ex-US ETF

佔比0.01%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據